Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118098 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL2581432 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL18689610 | 0.81 | GPR119 (0.46) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL18689594 | 0.81 | GPR119 (0.53) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL2579312 | 0.80 | GPR119 (0.46) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL1118173 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL7715739 | 0.79 | RECQL (0.48) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL3144261 | 0.77 | GPR119 (0.60) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL31192638 | 0.76 | TRPV3 (0.52) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL29183376 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2THRBGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3493807-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CymaBay Therapeutics, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2018026890-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2018-01-25 | — | — | US | disclosed |
| US-9737537-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170105993-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150239881-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2280704-B1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8227495-B2 | 2,4-disubsituted thiazoles and pharmaceutical compositions thereof | METABOLEX INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2280704-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100130511-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-04-08 | — | — | US | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2111107-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | Metabolex Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009123992-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008083238-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | SMN1; SMN2 3492/4885THRB 141/4885GAA 568/4885 |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | GPR119, GIPR, GLP1R | SMN1; SMN2 2793/4885THRB 886/4885GAA 1081/4885 |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | GPR119, GLP1R, DPP4 | SMN1; SMN2 2178/4885THRB 852/4885GAA 585/4885 |
| US-20150239881-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | SMN1; SMN2 3492/4885THRB 141/4885GAA 568/4885 |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | GPR119, GIPR, GLP1R | SMN1; SMN2 2793/4885THRB 886/4885GAA 1081/4885 |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | SMN1; SMN2 3492/4885THRB 141/4885GAA 568/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | SMN1; SMN2 1047/4885THRB 1958/4885GAA 14/4885 |
| US-20170105993-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | SMN1; SMN2 3492/4885THRB 141/4885GAA 568/4885 |
| US-20100130511-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | SMN1; SMN2 3492/4885THRB 141/4885GAA 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.